<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996239</url>
  </required_header>
  <id_info>
    <org_study_id>19-126</org_study_id>
    <nct_id>NCT03996239</nct_id>
  </id_info>
  <brief_title>Researching the Effect of Aerobic Exercise on Cancer</brief_title>
  <official_title>Exercise as Interception Therapy: A &quot;Proof-of-Concept&quot; Digitized Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to answer the following question: Will aerobic exercise (exercise
      that stimulates and strengthens the heart and lungs, and improves the body's use of oxygen)
      change the biomarkers (signs of disease) found in the blood?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with variant allele frequency (VAF)</measure>
    <time_frame>2 years</time_frame>
    <description>measured by targeted CH panel in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in residual tumor burden (Solid tumor group)</measure>
    <time_frame>2 years</time_frame>
    <description>measured by the amount of circulating tumor DNA (ctDNA)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>patients with clonal hematopoiesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise (walking)</intervention_name>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
    <arm_group_label>patients with clonal hematopoiesis</arm_group_label>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>plasma samples</intervention_name>
    <description>Plasma samples will be obtained at baseline.</description>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>fasting blood</description>
    <arm_group_label>patients with clonal hematopoiesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1: CH

          -  CH called by MSK practices as documented by an MSK physician

          -  Age ≥18 yrs

          -  Completion of all anticancer therapy

          -  High risk of cardiovascular disease defined by presence of at least one of the
             following:

               -  Age ≥60

               -  Prior treatment with chemotherapy

               -  Prior left-sided breast and/or chest wall radiotherapy

               -  Currently receiving or previously received androgen deprivation therapy Prior
                  bone marrow transplant

               -  History of smoking

               -  Currently treated for one or more cardiovascular risk factors (i.e.,
                  hypertension, diabetes, hyperlipidemia)

          -  Performing less than 150 minutes of structured moderate-intensity or
             strenuous-intensity exercise per week, as evaluated by self-report

          -  Willingness to comply with all study-related procedures

        Cohort 2: Solid Tumor

          -  Patients at risk of harboring circulating tumor DNA as defined by one of the
             following:

               -  Histologically confirmed stage III (i.e., high risk of recurrence) colorectal
                  cancer within 2 years of completion of all adjuvant therapy.

               -  Histologically confirmed stage III breast cancer with residual disease after
                  neoadjuvant therapy and within 12 months of completing (neo)adjuvant chemotherapy

               -  Patients with metastatic breast cancer and radiographic stable disease or NED for
                  ≥6 months and not currently receiving chemotherapy (endocrine therapy and
                  anti-HER2 antibodies allowed)

          -  Age ≥ 18 yrs

          -  Performing less than 150 minutes of structured moderate-intensity or
             strenuous-intensity exercise per week, as evaluated by self-report

          -  Willingness to comply with all study-related procedures

        Exclusion Criteria:

          -  Concurrent use of any form of antitumor therapy (endocrine therapy and anti-HER2
             antibodies allowed)

          -  Enrollment onto any other interventional investigational study

          -  Any other current diagnosis of invasive cancer or hematologic cancer of any kind

          -  Any other condition or intercurrent illness that, in the opinion of the investigator,
             makes the subject a poor candidate for study participation.

          -  Mental impairment leading to inability to cooperate

          -  Any of the following contraindications to exercise:

               1. Acute myocardial infarction within 3-5 days of any planned study procedures;

               2. Unstable angina

               3. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise

               4. Recurrent syncope

               5. Active endocarditis

               6. Acute myocarditis or pericarditis

               7. Symptomatic severe aortic stenosis

               8. Uncontrolled heart failure

               9. Acute pulmonary embolus or pulmonary infarction within 3 months of any planned
                  study procedures

              10. Thrombosis of lower extremities within 3 months of any planned study procedures

              11. Suspected dissecting aneurysm

              12. Uncontrolled asthma

              13. Pulmonary edema

              14. Respiratory failure

              15. Acute non-cardiopulmonary disorders that may affect exercise performance

          -  Room air desaturation at rest ≤ 85%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Iyengar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neil Iyengar, MD</last_name>
    <phone>646 888-8103</phone>
    <email>iyengarn@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lee Jones, PhD</last_name>
    <phone>646 888-8103</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-8103</phone>
    </contact>
    <contact_backup>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact_backup>
    <investigator>
      <last_name>Neil Iyengar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aerobic Exercise</keyword>
  <keyword>19-126</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

